Acute changes in sexual function, hormonal profiles, and psychological status following intensity-modulated radiotherapy in male patients with nasopharyngeal carcinoma

• by Yan Xiong, Weiying Deng, Yanxian Tan, Shaoli He

• June 2, 2026

Case Report: A rare case of over 45 years’ survival in a patient with tonsillar adenoid cystic carcinoma

• by Mingzhu Wang, Tingyao Ma, Yue Zhao, Shujing Zhang, Xuelian Wang, Guoliang Yang, Xi Zhao, Yixuan Liu, Tian Ye, Mengmeng Li, Jun Wu, Lanlan Xuan, Xiaohong Chen, Zheng Yang

• June 2, 2026

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

• by

• June 1, 2026

• 4 min

Bibliometric analysis of exercise and cancer prognosis research: trends, thematic evolution, and global collaborations (2015–2024)

• by Xiaodong Wang, Di Xiong, Qianqian Wang, Yiping Huang, Gouping Ding, Yixuan Tang, Songli Cui

• June 2, 2026